Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis

European Respiratory Journal

Volumn 33, Issue 2, 2009, Pages 305-311

  Douglas, T A ^a,b   Brennan, S ^b   Gard, S ^b   Berry, L ^b   Gangell, C ^b   Stick, S M ^a,b   Clements, B S ^a   Sly, P D ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bronchoalveolar lavage; Children; Cystic fibrosis; Eradication; Microbiological surveillance; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFANT; INFECTION PREVENTION; LUNG FIBROSIS; LUNG LAVAGE; MALE; PEDIATRIC PHYSIOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BRONCHOALVEOLAR LAVAGE FLUID; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; INFLAMMATION; INTERLEUKIN-1BETA; LEUKOCYTE ELASTASE; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TIME FACTORS;

EID: 59649123905     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00043108     Document Type: Article

References (27)

1. Accurso FJ. Early pulmonary disease in cystic fibrosis. Curr Opin Pulm Med 1997; 3: 400-403.
2. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1197-1204.
3. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
4. Brennan S, Hall GL, Horak F, et al. Correlation of forced oscillation technique in preschool children with cystic fibrosis with pulmonary inflammation. Thorax 2005; 60: 159-163.
5. Wagener JS, Kahn TZ, Copenhaver SC, Accurso FJ. Early inflammation and the development of pulmonary disease in cystic fibrosis. Pediatr Pulmonol Suppl 1997; 16: 267-268.
6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
7. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32: 277-287.
8. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2006. Bethesda, 2008. Available from www.cff.org/UploadedFiles/research/ ClinicalResearch/2006%20Patient %20Registry%20Report.pdf Date last accessed: September 23, 2008.
9. Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J Pediatr 1993; 122: 854-860.
10. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-588.
11. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699-704.
12. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-849.
13. Griese M, Muller I, Reinhardt D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002; 21: 79-80.
14. Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004; 2: 104-110.
15. Munck A, Bonacorsi S, Mariani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001; 32: 288-292.
16. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-461.
17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335.
18. The French Cystic Fibrosis Registry. Report on 2005 data of the National Cystic Fibrosis Observatory. Paris 2007. Available from www.vaincrelamuco.org/e- upload/pdf/rfm-report-on-2005-data-in-english.pdf Date last accessed: September 23, 2008.
19. UK Cystic Fibrosis Trust. CF Registry - Annual Data Reports. Available from www.cftrust.org.uk/aboutcf/publications/cfregistryreports/ Date last accessed: September 23, 2008.
20. Cystic Fibrosis in Australia. Australian National Cystic Fibrosis Data Registry - 2005. Available from www. cysticfibrosis.org.au/projects/ dataregistry/ Date last accessed: September 23, 2008.
21. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996; 21: 267-275.
22. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28: 321-328.
23. Delacourt C, Herigault S, Delclaux C, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol 2002; 26: 290-297.
24. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183: 444-452.
25. Speert DP, Farmer SW, Campbell ME, Musser JM, Selander RK, Kuo S. Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. J Clin Microbiol 1990; 2: 188-194.
26. Gibson RL, Emerson J, Mayer-Hamblett N, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42: 610-623.
27. Gutierrez JP, Grimwood K, Armstrong DS, et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001; 17: 281-286.